3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Gastrointestinal
1
Conditions
Stomach Neoplasms
1
Peritoneal Neoplasms
1
Ovarian Neoplasms
1
Carcinoma, Ovarian Epithelial
1
Interventions
pembrolizumab
26
Paclitaxel
22
Oxaliplatin
20
Nivolumab
16
Docetaxel
16
Capecitabine
16
Cisplatin
15
Fluorouracil
11
Cyclophosphamide
11
fludarabine
10
S 1 (combination)
10
Trastuzumab
9
Irinotecan
9
Carboplatin
8
Leucovorin
7
tislelizumab
6
aldesleukin
5
Ramucirumab
5
Interleukin-2
5
Gemcitabine
5
Drug Therapy
5
Bevacizumab
5
sintilimab
4
fludarabine phosphate
4
apatinib
4
Radiotherapy
4
Everolimus
4
regorafenib
3
olaparib
3
durvalumab
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Stomach Neoplasms
×
genexol-PM
×
Clear all
NCT03618758
2023-12-05
IPLUS
Seoul National University Bundang Hospital
Phase 1/2
Completed
35 enrolled